Dear ISSWSH Member,
We would like to follow up on the exciting news that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. As previously informed, flibanserin will be marketed with the trade name Addyi.
As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, ISSWSH would like to inform you that healthcare prescribers and pharmacies can now complete training to become certified to prescribe or dispense the medication through the Addyi Risk Evaluation and Mitigation Strategy (REMS) Program. Read more ...
Dear ISSWSH Members
Since the previous terminology of vulvodynia was accepted by the International Society for the Study of Vulvovaginal Disorders (ISSVD) in 2003, studies have explored possible causative factors and treatment options. The International Society for the Study of Women's Sexual Health (ISSWSH), The International Society for the Study of Vulvovaginal Disorders (ISSVD) and the International Pelvic Pain Society (IPPS) believed there was an unmet medical need for a comprehensive, evidence-based set of vulvovaginal pain diagnoses that can be easily utilized by both expert and non-expert healthcare providers to establish diagnoses in their patients and to guide treatment. Therefore we discussed the possibility of revision of 2003 terminology and organized an ISSWSH sponsored international meeting in order to reach a consensus on the terminology of vulvar pain, April 8 - 9, 2015 in Annapolis, Maryland. The American College of Obstetricians and Gynecologists (ACOG) and the National Vulvodynia Association (NVA) were also represented.
Read more ...
Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from hypoactive sexual desire disorderPUBLISHED: TUESDAY, AUGUST 18, 2015
Dear ISSWSH members,
It is with tremendous excitement that we share the announcement that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose members voted 18-6 for approval.